{
  "symbol": "BSLKW",
  "company_name": "Bolt Projects Holdings Inc WT",
  "ir_website": "https://www.boltprojectsholdings.com/",
  "structured_data": [
    {
      "section_name": "Financial Reports",
      "links": [
        {
          "title": "2024 Investor Presentation",
          "url": "https://irp.cdn-website.com/8deee57f/files/uploaded/2024-11-07_-_Bolt_Projects_Holdings_Investor_2024_Presentation_%282%29.pdf",
          "content": "INVESTOR PRESENTATION\nNOVEMBER 2024\n1\nTHE BEST DAYS At Bolt, we believe that the best days of our planet are\nahead of us.\nARE AHEAD\nBecause where some see a tree, we see a template.\nWhere some see a flower, we see a framework.\nOF US Where some see a spider’s web, we see a solution.\nThis is where billions of years of evolution meets the\nnewest advances in biotechnology.\nWhere we unlock nature’s blueprints and cultivate\nmaterials that are more beneficial to people and this\namazing ecosystem we call home.\nThis is the recipe for a more promising future.\nAnd we’ll be supplying the ingredients.\nInspired by nature.\nPropelled by science.\nDriven to create way better materials for a way better\nworld.\n2\nINTRODUCTION—WHO IS BOLT PROJECTS HOLDINGS?\nBy harnessing the power of\nBOLT IS\nnature’s materials, we create\nPIONEERING scientifically advanced, clean,\nluxurious ingredients that help\nA NEW beauty brands meet their\ncustomers’ demands for\nGENERATION\nperformance and sustainability.\nOF BIOTECH\nOver the last decade and with $300M+ invested,\nBolt Projects has decoded over 20,000 natural\nINGREDIENTS\nmaterials, scaling a variety from bench, to pilot,\nto fully commercialized.\nFOR HAIR CARE,\nOur products and processes are highly proprietary\n— protected by an intellectual property portfolio\nSKINCARE, AND anchored by 52 granted patents and 176 pending\npatent applications.\nCOLOR COSMETICS\nMany of our materials are actively moving through\nthe innovation pipeline and, we believe, are\nprimed for commercialization.\n3\nCOMPANY OVERVIEW\nOUR PLATFORM OUR APPROACH OUR TECHNOLOGY\nA collection of patented materials built on Optimizes manufacturing and simplifies Bolt’s first commercialized tech is our\nshared technology and functional benefits, regulatory compliance, allowing Bolt to Vegan Silk Technology Platform, which\ndesigned to streamline development and bring innovations to market faster and includes b-silk™ and newly expanded\noffer versatile solutions to common more efficiently. xl-silk™ ingredients.\nindustry challenges.\nEfficacious alternatives to silicone\nBOLT’S\nelastomers with 20+ proven functional\nVEGAN SILK benefits—\nTECHNOLOGY Made through fermentation, our vegan silks are collection complex\npolypeptides that act as a lightweight, film-forming alternative to silicone\nelastomers — a commonly used ingredient under increasing regulatory and\nPLATFORM consumer scrutiny due to concerns about their impact on human health and the\nenvironment.\nOur platform of vegan silks deliver 20+ clinically-proven benefits, are fully\nbio-based, and biodegradable, providing formulators the ability to incorporate\nthem into products without regulatory limitation.\n4\nMARKET OVERVIEW\nVEGAN SILK’S\nSILICONE MARKET\nMARKET\nOVERVIEW\nOPPORTUNITY\n1 TAM: $3.0B to $3.9B\nSilicone Elastomers in\nPersonal Care and Consumer\nB-silk™ competes in $3B+\nGoods Market\ncategory that requires new\nsolutions—\n$6.3B to 2\n$10B\n+ Vegan Silk materials have a wide range of applications and Global Silicone\nElastomer\nare designed to replace silicone elastomer and other\nMarket 3 $16.7B to\ningredients in the cosmetic formulations.\n$19.9B\n+ This represents a $3B+ market opportunity where regulatory Global Silicone\nMarket\nconstraints and consumer preference are demanding\nalternative sustainable solutions.\n+ Regulatory pressures, including European Union zero-waste\nregulations by June 1, 2027 (Regulation (EU) 2023/2055, and\nRegulation 2024/1328), and consumer preferences are forcing\nbrands to reconsider their use of silicone elastomers.\n5\nSALES—WHAT CUSTOMERS ARE BUYING B-SILK™?\nB-SILK’S GROWING MARKET\nPRESENCE\nBolt has validated multiple applications for\nb-silk™ — with products in market across\ncategories\n+ B-silk™ first came to market in haircare as part of Vegamour’s GRO Revitalizing\nShampoo and Conditioner, powering their proprietary Karmantin™ offering.\n+ Recently, b-silk™ delivered a mineral sunscreen with Freaks of Nature™ debuting in\ntwo SKUs — the Daily Defender SPF30 and the Peak Performance SPF50.\n+ As early as the first quarter of 2025, b-silk™ will be featured as a key ingredient in a\ncolor cosmetic product from a well-known brand, marking a significant milestone\nin its adoption by the beauty industry.\n+ Later in 2025, b-silk™ will expand into the professional haircare segment with a\nhigh-performance hair care line using an exclusive b-silk™ development,\nshowcasing its versatility and efficacy across beauty segments.\n6\nSALES—WHAT DRIVES TIMELINES?\nSALES CYCLE DRIVEN BY INDUSTRY\nESTABLISHED PROCESSES\nBeauty and Personal Care offers sustained\ndemand with long lead times to launch—\n+ The multi-faceted sales cycle for cosmetics ingredients, can range from 8 to 24\nmonths — mainly driven by the regulatory requirements governing the beauty\nindustry.\n+ In addition, brands have unique cycles for new product launches, which further\nextends time required to bring new ingredients to market.\n+ While lengthy, the process is delivering positive results as b-silk™ continues to\ndemonstrate both efficacy and high consumer satisfaction with each new product\nlaunch.\n+ Order volume growth occurs as our ingredient penetrates additional products and\nbrands within a customer’s portfolio.\n+ Furthermore, successful launches within these segments are expected to drive new\ncustomer adoption, establishing a proven value proposition.\n7\nSALES—HOW DO WE SELL B-SILK™ ?\nBOLT’S TARGETED\nSALES PROCESS—\nSALES FUNNEL FOR QUALIFIED LEADS\nAwareness\n+ Identification and qualification of brand customers that\nPresentation Done\nbenefit from Bolt’s platform offerings\n+ Engaging in a discovery process to align with their needs\nInterest\nNDA in Place\n+ Delivering material samples for research & development of\nnew or existing commercial products\n+ Brands finalize formula development and initiate Intent\nregulatory & safety testing, and claim validation Sample Sent\n+ Brand allocation of new products into marketing calendar\nConsideration\n+ Bolt delivers materials for production R&D in Progress\n+ Brands begin production and initiate go-to-market\nstrategy Decision\nProduct\nApproval &\nForecast\n8\nOPERATIONS—HOW DO WE MAKE B-SILK™?\nA PROPRIETARY INGREDIENT\nBACKED BY A PROPRIETARY\nBIO-MANUFACTURING PROCESS\n+ Our silk technology started over a decade ago, and Bolt has successfully\nmanufactured with 10+ contract manufacturing organizations (CMOs) over this\nperiod, demonstrating consistent tech-transfer feasibility across multiple production\npartners.\n+ Today, all manufacturing activities are outsourced, with a major Good\nManufacturing Practice (GMP) bio-manufacturer as our lead contract manufacturing\npartner. Together, we are focused on driving operational efficiencies and\nimplementing process improvements to support our mutual growth objectives.\n+ Over the past three years, this partnership has achieved over 80% in\nmanufacturing cost reductions, with an additional double-digit reduction\nanticipated in 2025.\nBOLT’S\nPROCESS Modeling of Computational Reprogramming Utilize white Purification and refining\nENCAPSULATED polypeptide protein design of yeast to produce the biotechnology process to obtain the\nsequences novel materials desired protein (fermentation) to final product\nproduce the protein\n9\nRESEARCH & DEVELOPMENT—HOW DO WE EXPAND AND DEVELOP NEW PLATFORMS?\nBOLT’S INNOVATION &\nCOMMERCIALIZATION PIPELINE\n+ Bolt has invested $300M+ over a decade in exploring a wide range of materials.\n+ This extensive silk background, and other developed technologies, provides Bolt with\na back-catalog of innovation to diversify our Vegan Silk Technology Platform\nand create new Platforms at an accelerated pace.\n+ Our current focus is optimizing our commercialize technology and expanding our\nsilk offering with specific target benefit by segment.\n+ We operationalize our R&D efforts by engaging external capabilities and\ninfrastructure offered within the biotech industry, such as our ongoing\ncollaboration with Ginkgo Bioworks.\n+ This approach enables Bolt to deliver innovation without the significant upfront\ncapex investments and tap an almost infinite technical talent pool, benefiting from\nGinkgo’s best-in-class facilities and talent.\nIDENTIFY FIND BIO BASED INITIATE DEFINE G0-TO-MARKET CUSTOMER FEEDBACK\nMARKET NEED SOLUTION DEEP R&D (GTM) STRATEGY & SCALE UP\nBOLT’S\nINNOVATION\nPIPELINE Market Opportunity Early Research & Material & Product Market Fit & Price Manufacturing &\nAssessment Techno-Economic Analysis Development Positioning Product Line Expansion\n10\nECONOMIC MODELING\nATTRACTIVE GROSS MARGINS\nAT SCALE\nLONG TERM MODEL\nRevenues\n— Due to customer launch plans and the nature of the distribution channel we\nsell into, deliveries of b-silk™ will vary from quarter to quarter. We believe that the best\nGross Margin 60%\nmeasure of our traction is sales and deliveries over the prior twelve months.\nR&D % of Sales 13%\nGross Profits\n— In order to support our fixed costs, we need to focus on driving\nrevenue growth at a manufacturing cost that supports attractive gross margins. We believe\nS&M % of Sales 15%\nthat at scale, b-silk™ will produce 60%+ gross margins.\nG&A % of Sales 12%\nOperating Expenses\n— Outside of working capital, our principal cash funding\nrequirement is driven by supporting our operating expenses. Our operating model requires a EBITDA Margin 20%\nsmall, professional team of sales, manufacturing, research, and G&A professionals. We believe\nwe can scale significantly with the existing infrastructure.\nEBITDA\n— By maintaining a reasonable and mostly fixed operating cost structure, we\nbelieve that investors will benefit from this scale as incremental gross profits translate into\npositive EBITDA / cash flow.\n11\nFINANCIALS\nBOLT PROJECTS HOLDINGS\nFINANCIAL RESULTS\n(In Thousands)\n2022 2023 2024 2025\nSales $346 $3,441 $1,000 $4,500\nGross Profit -$388 -$1,405 – Positive\nR&D $15,857 $9,630 – –\nS&M $1,699 $866 – –\nG&A $35,105 $18,757 – –\nEBITDA** -$49,015 -$20,602** – –\n* Certain expenses previously recorded as G&A have been reclassed to R&D or S&M. This classification adjustment was made to better reflect the\nnature of the expenses in accordance with U.S. GAAP. There was no impact on our total expenses, net income, or earnings per share.\n** See slide 15 for additional information about non-GAAP financial measures and slide 13 for a reconciliation of Adjusted EBITDA.\n12\nFINANCIALS\nBOLT PROJECTS HOLDINGS\nADJUSTED EBITDA RECONCILIATION\n(In Thousands)\n2022 2023\nGAAP net income (loss) $ (51,701) $(57,720)\nInterest expense 914 3,503\nDepreciation 1,645 1,088\nEBITDA $ (49,142) $ (53,129)\nNon-GAAP adjustments:\nLoss on lease termination – 319\nLease, property and equipment impairment – 21,559\nNon-cash fair value remeasurements of convertible notes, (1,032) 565\nwarrant, and share-based liabilities\nBridge note issuance costs – 3,257\nRestructuring costs – 3,973\nStock-based compensation 1,159 643\nLoss on supply agreement termination – 2,211\nAdjusted EBIDTA $ (49,015) $ (20,602)\n13\nENDNOTES / DISCLAIMER\nCAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS\nThis presentation contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts\ncontained in this communication, including statements regarding the Company’s new products, its market potential and market adoption, customer launches, the\nCompany’s business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify\nforward-looking statements by terminology such as “anticipate,” “believe,” “budget,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “might,”\n“plan,” “possible,” “potential,” “predict,” “project,” “should,” “strive,” “will” or the negatives of these terms or variations of them or similar terminology. Forward-looking\nstatements include, without limitation, the Company’s expectations concerning the outlook for the business, productivity, plans, and goals for future operational\nimprovements and capital investments, operational performance, future market conditions or economic performance and developments in the capital and credit\nmarkets, and expected future financial performance, as well as any information concerning possible or assumed future results of operations of the Company.\nForward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied\nin those statements. Important factors that could cause such differences include, but are not limited to: the Company’s history of net losses and ability to achieve or\nmaintain profitability in the future; the Company ability to execute its business plan and adequately control its expenses or raise additional capital on favorable terms, if\nat all; the Company’s ability to continue as a going concern; the Company ability to generate sufficient cash to service all of its debt obligations; the Company’s\ndependence on sales of its b-silk™ product; the Company’s ability to manage growth effectively; the Company’s reliance on a single or limited manufacturing partners\nand manufacturing facilities for the production of b-silk™; costs of and availability for b-silk™ and the Company’s future products that are out of the Company’s control;\npricing pressures if the Company’s costs of producing b-silk™ materially increase; the Company’s limited experience in marketing and selling b-silk™; market acceptance\nof from consumer product companies; the Company’s ability to protect adequately its patents and other intellectual property assets; government regulations and private\nparty actions relating to the marketing and advertising of cosmetic products that include b-silk™ or other products the Company develops may restrict, inhibit or delay\nits ability to sell such products; and the other risks and uncertainties discussed under the caption “Risk Factors” included in the Company’s prospectus on Form 424(b)(8)\nfiled with the SEC on October 2, 2024, as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC’s website at\nwww.sec.gov and the Investors section of the Company’s website at www. boltthreads.com.\nThe Company cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available\nas of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. The Company undertakes no\nobligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law.\n14\nENDNOTES / DISCLAIMER\nNON-GAAP FINANCIAL MEASURES\nIn addition to the financial measures presented in this release in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”), the Company has included certain\nnon-GAAP financial measures in this release, including EBITDA and Adjusted EBITDA. The Company's non-GAAP financial measures should not be considered as an\nalternative to net income (loss) as a measure of financial performance or any other performance measure derived in accordance with GAAP and should not be construed as\nan inference that the Company's future results will be unaffected by unusual or non-recurring items. EBITDA is defined as net income (loss) adjusted for interest expense and\ndepreciation. Adjusted EBITDA is defined as net income (loss) adjusted for interest expense and depreciation and amortization, (gain)/loss on lease termination, lease\nproperty and equipment impairment, loss on extinguishment on convertible notes, non-cash fair value remeasurements of convertible notes, warrant and share-based\nliabilities, bridge note issuance costs, restructuring costs and stock-based compensation.\n15"
        }
      ]
    }
  ]
}